BIONICIIE - Crespine Gel

LOCAL TREATMENT OF RH)ZARTHROA PROSPECTIVE RANDCRicardo Gabezas Gelaber1 Internal Medicine De ftment, Hos ital rABSTRACTBackground. Rhizarthrosis is a very frequent disease affecting about 29.5% of the general population (25-74 yeas old) and even more in special groups of population.Rhizarthrosis causes pain. functional and esthetic changes responsible of an important economic and social cost.Objective. The goal of this study was to evaluate the dficacy and the safety of repeated intra-articular infiltration of the trapezcmetacarpal joint with hyaluronic acid (HA.Suplasyn@) versus dexamethasone in patients suffering from rhizarthrosis.Methods. Patients satisfying the criteria of rhizarthrosis in any hand were randomized to Suplasyn@ or dexamethasone in an open, prospeçtive. comparative study. Aminimum pain score of 50 measured on a visual analogic scale (VAS from 0 to,|00) was required. The two groups received the same standard of care, thedexamethasone group received one infiltration of dexamethasone (4mg/1ml) and the Suplasyne group received 4 weekly infiltrations (5mg/0.5m1 each). Evaluation wasdone in both groups at baseline, one month and 6 months. The primary endpoint was the efficacy on the pain level as measured by the VAS score, the secondaryendpoints were the treatmentolerance and the overall treatment efiicacy evaluation by the patient and the physicianResults. Both groups had comparable VAS at baseline (596 in the group Suplasyn@ versus 59.0 in the dexamethasone group), A significant imprcr/ement of the VASscore (p

I: SUPLASYN@ VERSUS DEXAMETHASONEIIZED CONTROLLED STUDYArturo Rodriguez de la Serna 1Sant Pau i de la Santa Greu, Barcelona, Spainparison of pain intensity scored using a visual analog scale (VAS) at differentime points inpatients treated with Suplasyn@ or dexamethasonetl Su ptasyn@l Dexamethason eRESULTS8060402A0Base line 1month6 monthsBaseline1 month6 monthsp value [1]1 month vsbaseline6 months vs 1monthSuplasyn*n=24Mean + SD VAS59.6 + 9.430.7 + 12.930.6 + 13.1